Company / Cash & Equivalents
FENNEC PHARMACEUTICALS INC. Cash & Equivalents History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$36.8M
FY2025
5-year range
$13.3M / $36.8M
FY2021-FY2025
Trend
+38.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $942,000 in FY2016 to $37M in FY2025.
Based on SEC 10-K filings.
$37M in FY2025 with a 10-year CAGR of +31.9%.
Improved from $13M to $37M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +31.9%
Key checks
Key Insights
- In FY2025, cash & equivalents increased 38.1% year-over-year.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.8M | +38.1% |
| FY2024 | $26.6M | +100.7% |
| FY2023 | $13.3M | -37.1% |
| FY2021 | $21.1M | -7.4% |
| FY2019 | $22.8M | -19.4% |
| FY2018 | $28.3M | +619.8% |
| FY2017 | $3.9M | +316.8% |
| FY2016 | $942.0K | -59.2% |
| FY2015 | $2.3M | +38.7% |
| FY2014 | $1.7M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026